MX9700429A - El uso de compuestos de tiazol y tiadiazol. - Google Patents
El uso de compuestos de tiazol y tiadiazol.Info
- Publication number
- MX9700429A MX9700429A MX9700429A MX9700429A MX9700429A MX 9700429 A MX9700429 A MX 9700429A MX 9700429 A MX9700429 A MX 9700429A MX 9700429 A MX9700429 A MX 9700429A MX 9700429 A MX9700429 A MX 9700429A
- Authority
- MX
- Mexico
- Prior art keywords
- thiazole
- receptor ligands
- dopamine receptor
- thiadiazole compounds
- compounds
- Prior art date
Links
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title abstract 2
- 150000004867 thiadiazoles Chemical class 0.000 title abstract 2
- 101150097070 Drd3 gene Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Lubricants (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
La presente invencion se refiere al uso de compuestos de tiazol y tiadiazol de la siguiente formula: donde R1, A, B y Ar tienen los significados establecidos en la descripcion. Los compuestos de conformidad con la presente invencion tiene una afinidad elevada para el receptor D3 de dopamina y pueden por consiguiente emplearse para tratar trastornos del sistema nervioso central.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4425145A DE4425145A1 (de) | 1994-07-15 | 1994-07-15 | Verwendung von Thiazol- und Thiadiazolverbindungen |
PCT/EP1995/002783 WO1996002249A1 (de) | 1994-07-15 | 1995-07-14 | Verwendung von thiazol- und thiadiazolverbindungen als d3 dopaminrezeptorligand |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9700429A true MX9700429A (es) | 1998-05-31 |
Family
ID=6523324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9700429A MX9700429A (es) | 1994-07-15 | 1995-07-14 | El uso de compuestos de tiazol y tiadiazol. |
Country Status (21)
Country | Link |
---|---|
US (1) | US5958923A (es) |
EP (1) | EP0768879B1 (es) |
JP (1) | JPH10502915A (es) |
KR (1) | KR100443216B1 (es) |
CN (1) | CN1152872A (es) |
AT (1) | ATE234616T1 (es) |
AU (1) | AU712422B2 (es) |
BR (1) | BR9508295A (es) |
CA (1) | CA2195240A1 (es) |
CZ (1) | CZ292909B6 (es) |
DE (2) | DE4425145A1 (es) |
ES (1) | ES2194918T3 (es) |
FI (1) | FI970149A0 (es) |
HU (1) | HUT77554A (es) |
IL (1) | IL114600A (es) |
MX (1) | MX9700429A (es) |
NO (1) | NO312154B1 (es) |
SI (1) | SI9520081B (es) |
TW (1) | TW414793B (es) |
WO (1) | WO1996002249A1 (es) |
ZA (1) | ZA955869B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
DE19728996A1 (de) * | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
DE69929704T2 (de) | 1998-10-08 | 2006-07-20 | Smithkline Beecham Plc, Brentford | Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) |
WO2001072306A1 (de) * | 2000-03-27 | 2001-10-04 | Basf Aktiengesellschaft | Verwendung von dopamin-d3-rezeptor-liganden zur behandlung von erkrankungen des zentralen nervensystems |
HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
WO2003074518A1 (en) * | 2002-03-06 | 2003-09-12 | Merck Patent Gmbh | Thiazole derivatives and their use d2- and 5-ht1a-receptor ligands |
US7605259B2 (en) | 2002-09-14 | 2009-10-20 | University Of North Texas Health Science Center At Fort Worth | Structurally rigid dopamine d3 receptor selective ligands and process for making them |
US20040204422A1 (en) | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
DE10358004A1 (de) | 2003-12-11 | 2005-07-14 | Abbott Gmbh & Co. Kg | Ketolactam-Verbindungen und ihre Verwendung |
US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
CA2550053C (en) | 2003-12-18 | 2013-01-22 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
DE102004027359A1 (de) * | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
DE602005018366D1 (de) | 2004-08-09 | 2010-01-28 | Abbott Gmbh & Co Kg | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen |
GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
US8933101B2 (en) * | 2007-04-23 | 2015-01-13 | Janssen Pharmaceutica Nv | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists |
DK2148873T3 (da) * | 2007-04-23 | 2012-11-26 | Janssen Pharmaceutica Nv | 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister |
WO2010012758A1 (en) * | 2008-07-31 | 2010-02-04 | Janssen Pharmaceutica Nv | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
US10870660B2 (en) | 2016-07-28 | 2020-12-22 | Shionogi & Co., Ltd. | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect |
JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する環式化合物 |
JPWO2019146739A1 (ja) | 2018-01-26 | 2021-01-07 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する縮環化合物 |
WO2023144764A1 (en) | 2022-01-29 | 2023-08-03 | Suven Life Sciences Limited | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1053085A (es) * | 1964-03-26 | |||
DE1695410A1 (de) * | 1967-04-20 | 1971-04-08 | Merck Patent Gmbh | Verfahren zur Herstellung von 1-(Thiazolyl-5-alkyl)-4-(pyridyl-2)-piperazinen |
US3522846A (en) * | 1968-10-04 | 1970-08-04 | Robert V New | Method and apparatus for production amplification by spontaneous emission of radiation |
US3717651A (en) * | 1970-04-20 | 1973-02-20 | Shell Oil Co | Thiazoles |
US4074049A (en) * | 1976-11-19 | 1978-02-14 | The Dow Chemical Company | Antithrombotic 1,3,4-thiadiazole |
NZ223654A (en) * | 1987-03-09 | 1990-03-27 | Janssen Pharmaceutica Nv | 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions |
US4943580A (en) * | 1987-03-09 | 1990-07-24 | Janssen Pharmaceutica N.V. | Anti-histaminic benzimidazole, imidazopyridine and purine derivatives |
US4935424A (en) * | 1988-05-27 | 1990-06-19 | Warner-Lambert Company | 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents |
FR2636628B1 (fr) * | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
DE3923675A1 (de) * | 1989-07-18 | 1991-01-24 | Basf Ag | Amonoalkylsubstituierte 2-aminothiazole und diese enthaltende therapeutische mittel |
US5273977A (en) * | 1990-11-05 | 1993-12-28 | Warner-Lambert Company | Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents |
DE4119758A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 2-amino-5-mercaptothiadiazole, ihre herstellung und verwendung |
DE4119757A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung |
DE4119756A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung |
DE4119755A1 (de) * | 1991-06-15 | 1992-12-17 | Basf Ag | Aminoalkylsubstituierte 2-amino-1,3,4-thiadiazole, ihre herstellung und verwendung |
ZA9610046B (en) * | 1995-12-01 | 1997-07-10 | Ciba Geigy | Process for preparing 2-chlorothiazole compounds |
-
1994
- 1994-07-15 DE DE4425145A patent/DE4425145A1/de not_active Withdrawn
-
1995
- 1995-07-14 SI SI9520081A patent/SI9520081B/sl not_active IP Right Cessation
- 1995-07-14 ZA ZA955869A patent/ZA955869B/xx unknown
- 1995-07-14 JP JP8504702A patent/JPH10502915A/ja not_active Ceased
- 1995-07-14 HU HU9700115A patent/HUT77554A/hu unknown
- 1995-07-14 DE DE59510596T patent/DE59510596D1/de not_active Expired - Lifetime
- 1995-07-14 CA CA002195240A patent/CA2195240A1/en not_active Abandoned
- 1995-07-14 MX MX9700429A patent/MX9700429A/es not_active IP Right Cessation
- 1995-07-14 CN CN95194140A patent/CN1152872A/zh active Pending
- 1995-07-14 AT AT95926897T patent/ATE234616T1/de not_active IP Right Cessation
- 1995-07-14 CZ CZ199794A patent/CZ292909B6/cs not_active IP Right Cessation
- 1995-07-14 US US08/765,915 patent/US5958923A/en not_active Expired - Lifetime
- 1995-07-14 WO PCT/EP1995/002783 patent/WO1996002249A1/de active IP Right Grant
- 1995-07-14 IL IL11460095A patent/IL114600A/xx not_active IP Right Cessation
- 1995-07-14 ES ES95926897T patent/ES2194918T3/es not_active Expired - Lifetime
- 1995-07-14 KR KR1019970700268A patent/KR100443216B1/ko not_active IP Right Cessation
- 1995-07-14 BR BR9508295A patent/BR9508295A/pt not_active Application Discontinuation
- 1995-07-14 AU AU31115/95A patent/AU712422B2/en not_active Ceased
- 1995-07-14 EP EP95926897A patent/EP0768879B1/de not_active Expired - Lifetime
- 1995-08-08 TW TW084108222A patent/TW414793B/zh not_active IP Right Cessation
-
1997
- 1997-01-14 NO NO19970164A patent/NO312154B1/no not_active IP Right Cessation
- 1997-01-14 FI FI970149A patent/FI970149A0/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE4425145A1 (de) | 1996-01-18 |
TW414793B (en) | 2000-12-11 |
WO1996002249A1 (de) | 1996-02-01 |
ATE234616T1 (de) | 2003-04-15 |
SI9520081A (en) | 1997-08-31 |
CA2195240A1 (en) | 1996-02-01 |
IL114600A (en) | 1999-11-30 |
DE59510596D1 (de) | 2003-04-24 |
NO970164L (no) | 1997-03-14 |
CZ9497A3 (en) | 1997-09-17 |
FI970149A (fi) | 1997-01-14 |
JPH10502915A (ja) | 1998-03-17 |
ES2194918T3 (es) | 2003-12-01 |
CN1152872A (zh) | 1997-06-25 |
US5958923A (en) | 1999-09-28 |
ZA955869B (en) | 1997-01-14 |
BR9508295A (pt) | 1998-01-13 |
NO970164D0 (no) | 1997-01-14 |
AU712422B2 (en) | 1999-11-04 |
EP0768879A1 (de) | 1997-04-23 |
NO312154B1 (no) | 2002-04-02 |
CZ292909B6 (cs) | 2004-01-14 |
IL114600A0 (en) | 1995-11-27 |
KR100443216B1 (ko) | 2004-11-20 |
KR970704438A (ko) | 1997-09-06 |
HUT77554A (hu) | 1998-05-28 |
SI9520081B (sl) | 2003-12-31 |
HU9700115D0 (en) | 1997-02-28 |
FI970149A0 (fi) | 1997-01-14 |
EP0768879B1 (de) | 2003-03-19 |
AU3111595A (en) | 1996-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9700429A (es) | El uso de compuestos de tiazol y tiadiazol. | |
MX9700430A (es) | El uso de compuestos heterociclicos. | |
ZA955868B (en) | Substituted pyrimidine compounds and the use thereof | |
MY119350A (en) | Propiophenone derivatives and process for preparing the same | |
MX9707980A (es) | Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos. | |
MX9503529A (es) | Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen. | |
ES2131842T3 (es) | Compuestos de triazol y su empleo como ligandos de dopamina-d3. | |
SI1000034T1 (en) | Substituted 6-alkylphenanthridines | |
ES8608524A1 (es) | Procedimiento para preparar 5h, 11h-pirrolo (2, 1-c)-(1, 4) benzoxazepinas sustituidas en posicion 11 | |
BG101220A (en) | N-substituted 3-azabicyclo (93.2.0) heptane derivatives,their preparation and use | |
MX9801938A (es) | Derivados de 3-beta-aminoazabiciclo-octano-naftamida o 3-beta-aminoazabiciclo-nonano-naftamida como agentes antipsicoticos. | |
MXPA98005355A (es) | Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central. | |
AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
MX9700125A (es) | Compuestos de pirimidina. | |
AU2178099A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
HU9600300D0 (en) | Thiocarbamoyl derivatives using as antimicrobial agents and process for producing of these | |
MY130771A (en) | 3-azabicyclo [3.1.0] hexane derivatives useful in therapy. | |
MX9705379A (es) | Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis vasodilatadora. | |
MX9708618A (es) | AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
PD | Change of proprietorship |
Owner name: ABBOTT GMBH & CO. KG |
|
MM | Annulment or lapse due to non-payment of fees |